Miravo Healthcare™ Announces Third Quarter 2021 Results

– Q3 2021 Adjusted Total Revenue – $17.1 million –
– Q3 2021 Adjusted EBITDA – $7.0 million –
– Blexten Canadian Prescriptions Increased 16% Year-Over-Year –
– Cambia Canadian Prescriptions Increased 5% Year-Over-Year –

Miravo to Host Conference Call/Audio Webcast November 15th at 11:00 a.m. ET

Mississauga, Ontario, Canada – November 15, 2021 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and nine months ended September 30, 2021. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, which are available on the Company’s website (www.miravohealthcare.com) and on SEDAR (www.sedar.com). All figures are in Canadian dollars, unless otherwise noted.

Read full release here.